Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases (TRACTS)
Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases: A Prospective Multicenter Trial(TRACTS)
Sponsor: Changhai Hospital
This PHASE2 trial investigates Brain Metastases and Non-small-cell Lung Cancer and is currently ongoing. Changhai Hospital leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Nov 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Changhai Hospital
- Fudan University
- Longhua Hospital
- RenJi Hospital
- Shanghai Armed Police Hospital
- Shanghai Changzheng Hospital
- Shanghai Chest Hospital
- Shanghai Pulmonary Hospital, Shanghai, China
- Wu Jieping Medical Foundation
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .